Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 8
Submit an article Journal homepage
260
Views
16
CrossRef citations to date
0
Altmetric
Drug Profile

IXIARO® updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis

Tomas Jelinek Berlin Center for Travel and Tropical Medicine, Jägerstrasse 67–69, 10117 Berlin, Germany. [email protected]
Pages 859-869 | Published online: 09 Jan 2014

References

  • Halstead SB, Jacobsen J. Japanese encephalitis vaccines. In: Vaccines. 6th Edition. Plotkin SA, Orenstein WA, Offit P (Eds). Saunders Elsevier, PA, USA (2012).
  • Japanese encephalitis vaccines: WHO position paper. Wkly Epidemiol. Rec. 81, 331–340 (2006).
  • Campbell GL, Hills SL, Fischer M et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull. World Health Organ. 89, 766A–774E (2011).
  • Solomon T, Thao TT, Lewthwaite P et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull. World Health Organ. 86, 178–186 (2008).
  • Tsarev SA, Sanders ML, Vaughn DW et al. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 18(Suppl. 2), 36–43 (2000).
  • Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10(12), S98–S109 (2004).
  • Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25(17), 3445–3453 (2007).
  • Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19(31), 4557–4565 (2001).
  • Ni H, Burns NJ, Chang GJ et al. Comparison of nucleotide and deduced amino acid sequence of the 5´ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75(Pt 6), 1505–1510 (1994).
  • Hombach J, Solomon T, Kurane I et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23(45), 5205–5211 (2005).
  • Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomized controlled trial. Lancet 370(9602), 1847–1853 (2007).
  • Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 26(34), 4382–4386 (2008).
  • Van Gessel Y, Klade CS, Putnak R et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers. Vaccine 29, 5925–5931 (2011).
  • Schuller E, Klade CS, Wolfl G et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15), 2188–2193 (2009).
  • Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralizing antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151–6156 (2008).
  • Dubischar-Kastner KL, Eder S, Jilma B et al. Persistence of antibodies 60 months after vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51 (Abstract LB-2357). Presented at: The ASTMH 60th Annual Meeting. PA, USA, 4–8 December 2011.
  • Hammon WM, Sather GE. Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am. J Trop. Med. Hyg. 22(4), 524–534 (1973).
  • Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro®, IC51. Vaccine 28, 5197–5202 (2010).
  • Eder S, Dubischar-Kastner K, Firbas C et al. Long-term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro®, IC51. Vaccine 98, 2607–2612 (2011).
  • Erra EO, Askling HH, Rombo L et al. A single dose of vero cell-derived Japanese encephalitiy (JE) vaccine (Ixiaro) effectively boosts imunity in travelers primed with mouse brain-derived JE vaccines. Clin. Infect. Dis. 55(6), 825–834 (2012).
  • Erra EO, Askling HH, Yoksan S et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin. Infect. Dis. 56(2), 267–270 (2013).
  • Woolpert T, Staples JE, Faix DJ et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 30(20), 3090–3096 (2012).
  • Kaltenböck A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 27(33), 4483–4489 (2009).
  • Dubischar-Kastner K,Cramer JP, Eder S et al. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO®, IC51, in elderly (Abstract). Presented at: the 13th Conference of the International Society of Travel Medicine. Maastricht, The Netherlands, 19–23 May 2013.
  • Duggan ST, Plosker GL. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs 69(1), 115–122 (2009).
  • Schuller KT, Klade C, Kaltenboeck A et al. First clinical trial of a Vero cell derived, inactivated Japanese encephalitis (JE) vaccine IC51 in pediatric population. Presented at: The ASTMH Annual Meeting. New Orleans, LA, USA, 7–11 December 2008.
  • Kaltenböck A, Dubischar-Kastner K, Schuller E et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28(3), 834–839 (2010).
  • Dubischar-Kastner K, Kadlecek V, Eder S et al. Safety and immunogenicity of the inactivated Japanese encephalitis vaccine Ixiaro®, IC51, in Filipino children aged 2 months to <18 years. Presented at: The 9th Asia Pacific Travel Health Conference. Singapore, 2–5 May 2012.
  • Dubischar-Kastner K, Hatzenbichler E, Cramer J et al. Interim safety and immunogenicity data for the inactivated Japanese encephalitis vaccine IXIARO®, IC51, in children from JE non-endemic countries. Presented at: The 9th Asia Pacific Travel Health Conference. Singapore, 2–5 May 2012.
  • Dubischar-Kastner K, Kaltenboeck A, Schuller E et al. Six months safety of a Vero-cell derived Japanese encephalitis vaccine, IXIARO, IC51, across Phase 3 trials and in a long term follow up cohort. Presented at: The ASTMH Annual Meeting. New Orleans, LA, USA, 7–11 December 2008 (Abstract 836).
  • Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis. 198(4), 493–499 (2008).
  • Schuller E, Klingler A, Dubischar-Kastner K et al. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®. Vaccine 29(47), 8669–8676 (2011).
  • Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines 7(5), 689–693 (2008).
  • Jelinek T. Ixiaro: a new vaccine against Japanese encephalitis. Expert Rev. Vaccines 8(11), 1501–1511 (2009).
  • Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 42(RR 1), 1–15 (1993).
  • Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 9(7), 921–931 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.